Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?
Authors:
- 9 April 2018
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 28 (9) , 3760-3769
Abstract
To assess the added value of the dynamic contrast-enhanced sequence (DCE) to combination T2-weighted imaging (T2w) + diffusion-weighted imaging (DWI) in detecting prostate cancer (PCa) recurrence after HIFU (high-intensity focused ultrasound).Keywords
This publication has 38 references indexed in Scilit:
- The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic ReviewEuropean Urology, 2014
- Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working GroupEuropean Urology, 2013
- Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent diseaseBritish Journal of Radiology, 2012
- ESUR prostate MR guidelines 2012European Radiology, 2012
- Focal Therapy in Prostate Cancer—Report from a Consensus PanelJournal of Endourology, 2010
- Defining biochemical failure in patients treated with HIFUNature Reviews Urology, 2010
- The Index Lesion and the Origin of Prostate CancerNew England Journal of Medicine, 2009
- Prediction of locally recurrent prostate cancer after radiation therapy: Incremental value of 3T diffusion‐weighted MRIJournal of Magnetic Resonance Imaging, 2009
- Evaluating Localized Prostate Cancer and Identifying Candidates for Focal TherapyUrology, 2008
- Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2003